Author: Trapani, Jonathan B. ; Zuchowski, Yvonne ; Delpire, Eric ; Carty, Joshua S. ; Zhang, Mingzhi ; Harris, Raymond C. ; Zent, Roy ; Watts, Jason A. ; Arroyo, Juan Pablo ; Terker, Andrew S. ; Bock, Fabian

Hypothalamic vasopressin is required for appropriate urinary concentration. However, whether collecting duct-derived vasopressin is involved remains unknown. We developed a novel transgenic mouse model to induce tissue-specific deletion of vasopressin and showed that collecting duct-derived vasopressin is not required to concentrate or dilute urine.

01 Jun 2023·American Journal of Physiology-Renal Physiology

Insulin-regulated aminopeptidase is required for water excretion in response to acute hypotonic stress

Article

Author: Zuchowski, Yvonne ; Bhave, Gautam ; Keller, Susanna ; Carty, Joshua ; Harris, Raymond C. ; Watts, Jason A. ; Trapani, Jonathan B. ; Arroyo, Juan Pablo ; Bock, Fabian ; Terker, Andrew S. ; Zent, Roy ; Zhang, Mingzhi

Insulin-regulated aminopeptidase (IRAP) degrades vasopressin, but its role in urinary concentration and dilution is unknown. Here, we show that IRAP-deficient mice have a high urinary osmolality at baseline and are unable to excrete free water in response to water loading. These results reveal a novel regulatory role for IRAP in urine concentration and dilution.

01 Jan 2023·Toxicology Letters

Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan

Article

Author: Naisbitt, Dean J ; Meng, Xiaoli ; Hammond, Sean ; Mosedale, Merrie

Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of T-cell-mediated liver injury in a small number of patients. An important clinical conundrum following the contraindication of tolvaptan is whether administration of agents of similar pharmacological action and structure will be tolerated. Herein, we addressed this question through the exposure of tolvaptan-responsive T-cell clones to similar pharmaceutical agents. Whilst lixivaptan and conivaptan did not activate tolvaptan-responsive T-cells, mozavaptan evoked proliferative responses comparable with tolvaptan itself, indicating that there may be collateral immunological intolerance to this compound as a product of sensitization to tolvaptan.

100 Deals associated with Mozavaptan Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01855	Mozavaptan Hydrochloride	C03XA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyponatremia	JP	Otsuka Holdings Co., Ltd.	26 Jul 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Discovery	JP	Otsuka Pharmaceutical Co., Ltd.	-
Polycystic Kidney Diseases	Discovery	US	-	-
Postmyocardial infarction syndrome	Discovery	JP	Otsuka Pharmaceutical Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis